Acute ischemic stroke: Emergent evaluation and management

Emergency Medicine Clinics of North America

Volumn 20, Issue 3, 2002, Pages 609-630

  Thurman, R Jason ^a   Jauch, Edward C ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; INSULIN; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NITROPRUSSIDE SODIUM; PROLYSE; PROUROKINASE;

ACUTE DISEASE; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; EMERGENCY MEDICINE; FIBRINOLYTIC THERAPY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTHERMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROLOGIC EXAMINATION; PATIENT TRANSPORT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; TREATMENT INDICATION;

EID: 0036696952     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8627(02)00014-7     Document Type: Review

References (45)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association; 2000.
2. Jauch EC, Kissela B, McNeil P. Acute stroke management from neurology/neuro-vascular diseases. Sited from eMedicine.com, Inc., eMedicine Journal 2001 emedicine.com. Accessed March 5, 2001.
3. Kothari R, Pancioli A, Brott T, Broderick J. Thrombolytic therapy for cerebral infarction. Acad Emerg Med 1996;3:881-92.
4. Hakim AM. Ischemic penumbra: the therapeutic window. Neurology 1998;51(Suppl): S44-6.
5. Zivin JA. Factors determining the therapeutic window for stroke. Neurology 1998;50: 599-603.
6. American Heart Association. Textbook of advanced cardiac life support Dallas, TX: American Heart Association, 1997.
7. Jauch E. Ischemic anterior circulation stroke. From the Foundation for Education and Research in Neurological Emergencies Presentation at the SAEM Conference. Atlanta, GA, 2001.
8. Kothari R, Pancioli A, Liu T. Cincinnati Prehospital Stroke Scale: reproducibility and validity. Ann Emerg Med 1999;33:373-8.
9. Adams HP, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994;25:1901-14.
10. Kanter D, Kothari R, Pancioli A, et al. The Greater Cincinnati T-PA Experience After the NINDS Trial: does a longer time to treatment within the current three-hour window reduce efficacy? [abstract] Stroke 1999;30:244.
11. Pancioli AM, Broderick J, Kothari R, et al. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA 1998;279(16):1288-92.
12. Johnston SC, Gress DR, Browner WS. Short-term prognosis after emergency department diagnosis of transient ischemic attack. JAMA 2000;284(22):2901-06.
13. Kandel ER, Schwartz JH, Jessell TM, editors. Principles of neural science. Third edition. New York: Elsevier Science Publishing Co., Inc; 1991. p. 724-9.
14. Adams HP, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:126-31.
15. Culebras A, Kase CS, Masdeu JC, et al. Practice guidelines for the use of imaging in transient ischemic attacks and acute stroke: a report of the Stroke Council, American Heart Association. Stroke 1997;28:1480-97.
16. Schriger DL, Kalafut M, Starkman S, et al. Cranial computed tomography interpretation in acute stroke: physician accuracy in determining eligibility for thrombolytic therapy. JAMA 1998;279:1293-7.
17. Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med 2000;343:710-22.
18. Broderick J, Brott T, Barsan W, et al. Blood pressure during the first minutes of focal cerebral ischemia. Ann Emerg Med 1993;22:1438-43.
19. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19, 435 patients with acute ischemic stroke. Lancet 1997;349:1569-81.
20. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119(Suppl):S300-20.
21. Sandercock P. Is there still a role for intravenous heparin in acute stroke? No. Arch Neurol 1999;56:1160-1.
22. Grau AJ, Hacke W. Is there still a role for intravenous heparin in acute stroke? Yes. Arch Neurol 1999;56:1159-60.
23. Kay R, Wong KS, Lu YL, et al. Low-molecular-weight-heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-93.
24. Hommel M, for the FISS bis Investigators Group. Fraxiparin in Ischemic Stroke Study (FISS bis). Cerebrovasc Dis 1998;8(Suppl 4):S19.
25. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
26. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999;340:1781-7.
27. Hacke W, Kaste M, Fiechi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995;274:1017-25.
28. Hacke W, Kaste M, Fieschi C, et al. Randomised Double-blind Placebo-controlled Trial of Thrombolytic Therapy with Intravenous Alteplase in Acute Ischaemic Stroke (ECASS II). Lancet 1998;352:1245-51.
29. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999;282:2019-26.
30. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283:1151-8.
31. Sloan EP. Clinical use of tPA in acute ischemic stroke. From the Foundation for Education and Research in Neurological Emergencies Presentation at the SAEM Conference. Atlanta, GA, 2001.
32. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA 2000;283:1145-50.
33. Caplan LR, Mohr JP, Kistler JP, Koroshetz W. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis - not a panacea for ischemic stroke. N Engl J Med 1997;337:1309-10.
34. Grotta J. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA- the best current option for most patients. N Engl J Med 1997;337:1310-3.
35. Adams HP, Brott T, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke: a statement for health care professionals from a special writing group of the Stroke Council, American Heart Association. Circulation 1996;94:1167-74.
36. Chiu D, Krieger K, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice, Stroke 1998;29:18-22.
37. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II Study: a randomized controlled trial. JAMA 1999;282:2003-11.
38. Lewandowski C, Frankel M, Tomsick T, et al. Combined intravenous and intra-arterial r-tpa versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-605.
39. Pancioli A, Kothari R. Thrombolytic therapy for acute ischemic stroke. Air Med J 1999;18(2):56-61.
40. Ernst R, Pancioli A, Tomsick T, et al. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 2000;31:2552-7.
41. Ronning OM, Guldvog B. Stroke units versus general medical wards, I: twelve- and eighteen-month survival. A randomized controlled trial. Stroke 1998;29:58-62.
42. Barsan WG, Brott TG, Broderick JP, et al. Time of hospital presentation in patients with acute stroke. Arch Intern Med 1993;153:2558-61.
43. Kothari R, Jauch E, Broderick J, et al. Acute stroke: delays to presentation and emergency department evaluation. Ann Emerg Med 1999;33:3-8.
44. The National Institute of Neurological Disorders and Stroke. Proceedings of the National Symposium on Rapid Identification and Treatment of Acute Stroke. NIH Publication No. 97-4239. Marler JR, Winter-Jones P, Emr M, editors. Bethesda, MD: National Institutes of Health; 1997. p. 157-8.
45. Gresham GE, Alexander D, Bishop DS, et al. American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke: rehabilitation. Stroke 1997;28:1522-6.